1. Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial
- Author
-
Meiyu Lyu, Yi Yang, Jinlian Liu, Wenting Fei, Min Fu, Yunting Hong, Hongguo Rong, Chun Wang, Linyuan Wang, and Jianjun Zhang
- Subjects
Female melasma ,Lutai danshen baishao granules ,Clinical trial ,Efficacy ,Safety ,Traditional Chinese medicine ,Miscellaneous systems and treatments ,RZ409.7-999 - Abstract
Objective: To investigate the potential efficacy and safety of Lutai Danshen Baishao granules (LDBG) for treating female melasma associated with kidney deficiency and blood stasis patterns. Methods: A randomized, double-blind, placebo-controlled trial was conducted at the Third Central Hospital of Tianjin, China from March to December 2023. A total of 110 female patients with melasma linked to kidney deficiency and blood stasis were enrolled and treated with either LDBG or a placebo twice daily for 60 days. Efficacy was assessed through measures such as the total melasma area, reduced melasma area, reduction rate of melasma area, melasma color score, Melasma Area and Severity Index (MASI) score, and traditional Chinese medicine (TCM) symptom score scale. Safety assessments included routine blood and biochemical tests. Results: Participants in both groups were aged 52–63 years, with no significant differences. After the 2-month intervention, the total melasma area decreased in both groups; however, a greater reduction was observed in the test group [462.50 mm2 (12.81%) vs. 100.00 mm2 (3.11%), P
- Published
- 2025
- Full Text
- View/download PDF